PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies

Author(s): Amanda Black, Wen-Yi Huang, Patrick Wright, Tom Riley, Jerome Mabie, Sunitha Mathew, Lawrence Ragard, Sigurd Hermansen, Kelly Yu, Paul Pinsky, Philip C. Prorok, Neal D. Freedman, Robert N. Hoover

Journal Name: Reviews on Recent Clinical Trials

Volume 10 , Issue 3 , 2015

Become EABM
Become Reviewer
Call for Editor


The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), a large-scale, multi-institutional, randomized controlled trial, was launched in 1992 to evaluate the effectiveness of screening modalities for prostate, lung, colorectal, and ovarian cancer. However, PLCO was additionally designed to serve as an epidemiologic resource and the National Cancer Institute has invested substantial resources over the years to accomplish this goal. In this report, we provide a summary of changes to PLCO’s follow-up after conclusion of the screening phase of the trial and highlight recent data and biospecimen collections, including ancillary studies, geocoding, administration of a new medication use questionnaire, consent for linkage to Medicare, and additional tissue collection that enhance the richness of the PLCO resource and provide further opportunities for scientific investigation into the prevention, early detection, etiology and treatment of cancer.

Keywords: Cancer research, cohort, epidemiologic resource, PLCO, screening trial.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 27 September, 2015
Page: [238 - 245]
Pages: 8
DOI: 10.2174/157488711003150928130654
Price: $65

Article Metrics

PDF: 37